Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06830096 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Role of KATP Channel Loss in Type 2 Diabetes

Study acronym: BC
StatusRecruiting
PhaseNot applicable
Started2025-03-07
View on ClinicalTrials.gov ↗
Insulin is a hormone that is made by β-cells in the pancreas and when released into the bloodstream helps control blood sugar levels. Insulin release is regulated by electrical activity in the β-cell which is generated by the ATP-sensitive potassium (KATP) channel. While reduced KATP activity is associated with increased insulin secretion, animals lacking KATP exhibit reduced secretion. This crossover from hypersecretion to undersecretion with KATP loss mirrors insulin secretion during type 2 diabetes. Intriguingly, evidence from cell and animal models suggest that chronically stimulated β-cells can lose KATP revealing a possible role for KATP loss in the failure of insulin secretion and poor control of blood sugar observed in type 2 diabetes. This study will therefore examine insulin responses following ingestion of a single dose of a sulfonylurea called glipizide that inhibits KATP channels in people with and without type 2 diabetes. The goal is to determine whether KATP channel activity is reduced during type 2 diabetes progression.

Amendment history 2 changes detected by DataLookout

2026-08-11
critical
Primary completion pushed: 2026-03-31 → 2026-12-31
2026-08-11
minor
Completion pushed: 2026-07-01 → 2027-03-31
Trial Details
NCT Number NCT06830096
Lead Sponsor Washington University School of Medicine
Collaborators: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Conditions Obesity and Type 2 Diabetes
Enrollment 40 participants
Start Date 2025-03-07
Primary Completion 2026-12-31 (estimated)
Study Completion 2027-03-31 (estimated)
Updated on ClinicalTrials.gov 2026-08-10